Merck KGaA / MilliporeSigma (CDMO) vs SCTbio: CDMO Comparison
How does Merck KGaA / MilliporeSigma (CDMO) compare to SCTbio for Cell Therapy manufacturing?
Side-by-side comparison of Merck KGaA / MilliporeSigma (CDMO) and SCTbio on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Merck KGaA / MilliporeSigma (CDMO) has FDA inspections on record (2); SCTbio does not yet appear in the FDA inspection database.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- SCTbio has materially broader EMA GMP coverage (5 active certificates vs 2) — stronger EU footprint.
- Merck KGaA / MilliporeSigma (CDMO) appears as a manufacturing partner on more matched clinical programs (22 vs 0) — a broader sponsor book.
On a 13-modality CDMO landscape, both Merck KGaA / MilliporeSigma (CDMO) and SCTbio qualify as Cell Therapy manufacturers; Merck KGaA / MilliporeSigma (CDMO) carries the higher composite Signal Score for Cell Therapy programs in this comparison.
What to evaluate for Cell Therapy programs
Both Merck KGaA / MilliporeSigma (CDMO) and SCTbio qualify as Cell Therapy CDMOs. When choosing between them for Cell Therapy programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Autologous vs allogeneic
Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model.
Vector & raw materials
Most cell therapies need a viral vector. Confirm whether the CDMO makes vector in-house or coordinates an external supplier, and how that affects timelines.
Closed-system & cleanrooms
Closed, automated processing reduces contamination risk and labor. Ask about cleanroom grade, automation platforms, and parallel-suite capacity.
Cold chain & logistics
Cryopreservation and chain-of-custody are critical for living cells. Evaluate the CDMO's cold-chain and apheresis-to-infusion logistics.
Frequently asked: Merck KGaA / MilliporeSigma (CDMO) vs SCTbio
How does Merck KGaA / MilliporeSigma (CDMO) compare to SCTbio for Cell Therapy manufacturing?
On CDMO Signal's composite Signal Score, Merck KGaA / MilliporeSigma (CDMO) is 82/100 and SCTbio is 82/100; Merck KGaA / MilliporeSigma (CDMO) has 2 FDA inspections on record vs 0 for SCTbio; European coverage is 2 active EMA+MHRA certificates for Merck KGaA / MilliporeSigma (CDMO) vs 5 for SCTbio. Both are tracked in the CDMO Signal directory as Cell Therapy CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Merck KGaA / MilliporeSigma (CDMO) or SCTbio?
Both Merck KGaA / MilliporeSigma (CDMO) and SCTbio maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Merck KGaA / MilliporeSigma (CDMO) has 2 FDA inspections on record; SCTbio has 0.
How do Merck KGaA / MilliporeSigma (CDMO) and SCTbio compare on European GMP coverage?
Merck KGaA / MilliporeSigma (CDMO) holds 2 active EMA GMP certificates and 0 MHRA / UK certificates. SCTbio holds 5 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Merck KGaA / MilliporeSigma (CDMO) or SCTbio?
Merck KGaA / MilliporeSigma (CDMO) is matched to 22 ClinicalTrials.gov records as a manufacturing partner; SCTbio is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for Cell Therapy manufacturing — Merck KGaA / MilliporeSigma (CDMO) or SCTbio?
Both Merck KGaA / MilliporeSigma (CDMO) and SCTbio are tagged as Cell Therapy CDMOs in our directory, so both are credible options for Cell Therapy programs. The most important differentiator for Cell Therapy selection is typically autologous vs allogeneic: Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →